QNEC (Qualified Nonelective Contribution)

Qualified Nonelective Contribution (QNEC) refers to a type of employer contribution made to a 401(k) retirement plan on behalf of an eligible employee. Unlike elective contributions, which are made at the employee's discretion, QNECs are non-elective and are mandatory contributions made by the employer. These contributions are vital for ensuring the plan's compliance with certain Internal Revenue Service (IRS) regulations, particularly the nondiscrimination tests, such as the Actual Deferral Percentage (ADP) and Actual Contribution Percentage (ACP) tests. QNECs are designed to benefit employees who may not have made sufficient elective deferrals to pass these tests, thereby helping the plan remain qualified and tax-advantaged.

Examples:

  • Correcting ADP/ACP Testing Failures: Let's say a 401(k) plan fails the ADP/ACP nondiscrimination tests because highly compensated employees have contributed disproportionately higher amounts compared to non-highly compensated employees. To rectify this, the employer can make QNECs for the non-highly compensated employees to meet the compliance requirements.

  • Missed Deferral Opportunities: Sometimes, eligible employees may forget or choose not to make elective deferrals to their 401(k) accounts. In such cases, the employer can make QNECs on their behalf to boost their retirement savings without requiring any action from the employees.

  • Vesting Requirements: Employers may use QNECs to satisfy vesting requirements for certain employees. By doing so, they provide additional retirement benefits to these employees based on their service, irrespective of whether they made elective contributions or not.

In summary, QNECs play a crucial role in maintaining the tax-qualified status of 401(k) plans and help ensure that employees, particularly non-highly compensated ones, receive adequate retirement benefits while adhering to IRS regulations.

Next Up

Welcome to our latest release. We are excited for you to try the new features.
According to Mployer Insights’ 2026 analysis of 50,000+ employer health plans, prescription drugs account for over 25% of total benefit expenses, with Tier 4 specialty drugs driving the majority of high-cost claims. While Tier 4 copays average $123 with coinsurance requirements in 31% of plans, individual oncology therapies like Darzalex Faspro ($170,800/yr) and Keytruda ($158,200/yr) frequently exceed average individual stop-loss deductibles ($141,938). To mitigate exposure, self-funded employers are increasingly turning to independent, transparent PBM models and biosimilar substitution—which yields up to a 73% net cost reduction per patient.
Most U.S. employers now offer paid maternity leave beyond the legal minimum, but coverage varies widely once you look past the basics. According to Mployer Insights' 2026 analysis of more than 50,000 employer benefit plans, 68% of employers provide paid maternity leave on top of short-term disability, typically adding 8 extra weeks, and half now cover 100% of salary during the disability period. Support drops off from there: only 41% of employers offer paid bonding leave for non-birth parents, and advanced family-building benefits remain even less common, with just 28% covering IVF and 11% offering adoption financial assistance. The data suggests that while baseline maternity leave has become standard, more comprehensive family-building support is still the exception rather than the norm.